| P2093 | author name string | R de Wit | |
| | F Y F L de Vos | |
| P2860 | cites work | Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study | Q71067477 |
| | Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy | Q73042239 |
| | Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q73494793 |
| | Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma | Q73872746 |
| | Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study | Q28139358 |
| | Overview of gemcitabine triplets in metastatic bladder cancer | Q33186166 |
| | Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer | Q33328108 |
| | Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group | Q33330628 |
| | Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network | Q33337751 |
| | Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens | Q33344322 |
| | Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy | Q33347646 |
| | Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group | Q33362483 |
| | Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study | Q33364779 |
| | Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study | Q33365072 |
| | A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. | Q33372087 |
| | Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer | Q33500776 |
| | Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer | Q33501053 |
| | Overview of bladder cancer trials in the European Organization for Research and Treatment | Q35098007 |
| | Systemic chemotherapy in inoperable or metastatic bladder cancer | Q36320015 |
| | Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group | Q37172835 |
| | Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. | Q37474079 |
| | Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group | Q40636458 |
| | A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q40731377 |
| | Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point | Q41747152 |
| | Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse | Q43419722 |
| | A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer | Q43777231 |
| | Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study | Q43824740 |
| | A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma | Q44635857 |
| | Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy | Q44673128 |
| | Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. | Q46035514 |
| | Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. | Q51939874 |
| | Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial | Q59629290 |
| | Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. | Q64882384 |
| | A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors | Q68514585 |
| | Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern | Q69401186 |
| P433 | issue | 6 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 381-388 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Therapeutic advances in medical oncology | Q26842113 |
| P1476 | title | Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy | |
| P478 | volume | 2 | |